Deciphera Pharmaceuticals (NASDAQ:DCPH) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Thursday.
A number of other research firms have also commented on DCPH. B. Riley began coverage on shares of Deciphera Pharmaceuticals in a research report on Friday, February 16th. They set a “buy” rating and a $43.00 price target for the company. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.14.
DCPH opened at $25.57 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.35 and a quick ratio of 14.35. Deciphera Pharmaceuticals has a one year low of $15.15 and a one year high of $29.98.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Wednesday, March 28th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.19). research analysts expect that Deciphera Pharmaceuticals will post -2.36 EPS for the current year.
A number of large investors have recently made changes to their positions in DCPH. BlackRock Inc. grew its position in Deciphera Pharmaceuticals by 3,989.6% in the fourth quarter. BlackRock Inc. now owns 363,483 shares of the company’s stock worth $8,241,000 after acquiring an additional 354,595 shares in the last quarter. Sphera Funds Management LTD. grew its position in Deciphera Pharmaceuticals by 198.9% in the fourth quarter. Sphera Funds Management LTD. now owns 224,154 shares of the company’s stock worth $5,008,000 after acquiring an additional 149,154 shares in the last quarter. Emerald Advisers Inc. PA grew its position in Deciphera Pharmaceuticals by 37.6% in the fourth quarter. Emerald Advisers Inc. PA now owns 482,626 shares of the company’s stock worth $10,941,000 after acquiring an additional 131,886 shares in the last quarter. Geode Capital Management LLC purchased a new position in Deciphera Pharmaceuticals in the fourth quarter worth $2,735,000. Finally, Alyeska Investment Group L.P. purchased a new position in Deciphera Pharmaceuticals in the third quarter worth $1,968,000. Institutional investors own 48.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Deciphera Pharmaceuticals (DCPH) Raised to “Strong-Buy” at BidaskClub” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/14/deciphera-pharmaceuticals-dcph-raised-to-strong-buy-at-bidaskclub.html.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.